reports
Medpace Holdings Inc: 1 director
A director at Medpace Holdings Inc sold 39,342 shares at 404.764USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Stitch Fix Announces New Employee Inducement Grant
Stitch Fix Announces New Employee Inducement Grant SAN FRANCISCO, May 17, 2024 (GLOBE NEWSWIRE) -- Stitch Fix, Inc. (NASDAQ:SFIX), the leading online personal styling service, today announced that effective May 15, 2024, the compensation committee of the company’s board of directors granted restricted stock units (RSUs) to one new employee to acquire 118,722 shares of the company’s Class A common stock. One fourth of these restricted stock units will vest on June 12, 2024, and the remainder will vest in 3 equal quarterly installments of 1/4th over the next three subsequent quarterly RSU v...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
TWI TITAN INTERNATIONAL INC.
TNET TRINET GROUP INC.
RYI RYERSON HOLDING CORPORATION
PZZA PAPA JOHN'S INTERNATIONAL INC.
PII POLARIS INC.
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
JACK JACK IN THE BOX INC.
HURN HURON CONSULTING GROUP INC.
FIVE FIVE BELOW INC.
EXTR EXTREME NETWORKS INC.
EXPE EXPEDIA GROUP INC.
EXEL EXELIXIS INC.
EXAS EXACT SCIENCES CORPORATION
EVH EVOLENT HEALTH INC CLASS A
CLX CLOROX COMPANY
ACAD ACADIA PHARMACEUTICALS INC.
BF.B BROWN-FORMAN CORPORATION CLASS B
COHU COHU INC.
IONS IONIS PHARMACEUTICALS INC.
LEG LEGGETT & PLATT INCORPORATED
TAP MOLSON COORS BEVERAGE COMPANY CLASS B
THS TREEHOUSE FOODS INC.
WH WYNDHAM HOTELS & RESORTS INC.
BMY BRISTOL-MYERS SQUIBB CO. CEDEAR
SUZBY SUZANO SA
PGNY PROGYNY
ODP THE ODP CORPORATION
APA APA CORPORATION
PTLO PORTILLOS INC
STVN STEVANATO GRP SPA
FNA PARAGON 28 INC
SHLS SAKHALIN SHIPPING CO ORD
P RAILPOWER TECHNOLOGIES CORP COM
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
Amwell CEO Roy Schoenberg to Speak at Stanford Disability & Telehealth...
Amwell CEO Roy Schoenberg to Speak at Stanford Disability & Telehealth Conference Amwell CEO to join tech and health leaders from Apple, Stanford Health and others in discussing virtual care solutions that bolster accessibility Boston, May 16, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, today announced its Co-CEO and President, Roy Schoenberg, M.D., M.P.H., will speak at the at 12:15 PST on Saturday, May 18. The virtual conference explores barriers to telehealth enhancement for those with disabilities and the innovative solutions underway to advance hea...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of NextEra Energy, Inc., Florida Power & Light Company, and NextEra Energy Capital Holdings, Inc. and other ratings that are associated with these issuers. The review was conducted through a rating committee held on 10 May 202...
Lifeward Reports First Quarter 2024 Financial Results
Lifeward Reports First Quarter 2024 Financial Results Q1’24 revenue of $5.3M is up 340% vs. Q1’23 and at the midpoint of Lifeward’s guidance range Newly established Medicare payment for ReWalk Personal Exoskeleton favorably impacts Q1’24 results Medicare Administrative Contractors (“MACs”) approve 14 claims since fee schedule established MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is ...
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration...
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a minimal impact on Verrica’s cash position Common warts is one of the largest and most underserved p...
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Str...
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Se...
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in M...
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis —With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval with clinical outcomes to support the potential for confirmatory or full approval— SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clin...
- Wedbush Research
BLUE BLUEBIRD BIO INC.
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
AXTI AXT INC.
OSTK OVERSTOCK.COM INC.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
HPE HEWLETT PACKARD ENTERPRISE CO.
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
AVGO BROADCOM INC.
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
DELL DELL TECHNOLOGIES INC CLASS C
GBIO GENERATION BIO
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
MRVL MARVELL TECHNOLOGY INC
STX SEAGATE TECHNOLOGY HLDGS PLC
IKNA IKENA ONCOLOGY INC
AVTE AEROVATE THERAPEUTICS INC
DBD DIEBOLD NIXDORF INCORPORATED
Reliance Inc: 1 director
A director at Reliance Inc sold 5,000 shares at 294.360USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Allogene Therapeutics Announces Pricing of $110 million Offering of Co...
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of $2.90 per share. The gross proceeds from this offering are expected to be approximately $110 million, before deducting the underwriting discount and commi...
Cara Therapeutics Reports First Quarter 2024 Financial Results
Cara Therapeutics Reports First Quarter 2024 Financial Results Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. “Our notalgia paresthetica (NP) pivotal clini...
Allogene Therapeutics Reports First Quarter 2024 Financial Results and...
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Extended Territory Rights Substantially Increase Market Opportunity in 1L Consolidation LBCL and R/R CLL From More Than $6 Billion in the US to More Than $9.5 Billion in the Combined U.S., EU Member States and the United KingdomC...
- Matthew Weiss
- Michael Gerbino
- Scott Devitt
Relay Therapeutics to Host New Program and Platform Event on June 6, 2...
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024 Company to disclose new programs from existing unnamed pre-clinical pipeline CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that the company will host a New Program and Platform event on Thursday, June 6, 2024 from 8:00 to 10:00 a.m. ET. During the event, the company will disclose new programs from its existing pre-clinical p...
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results – Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company develop...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,150 shares of the Company’s common stock to four new employees (the “Inducement Gra...
SeaChange Completes Sale of Substantially All of its Assets to Enghous...
SeaChange Completes Sale of Substantially All of its Assets to Enghouse BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- . (OTC: SEAC) (“SeaChange” or the “Company”), a leading provider of video delivery, advertising, streaming platforms, and emerging Free Ad-Supported Streaming TV services (FAST) development, today announced that it has closed its previously announced transaction to sell substantially all of SeaChange’s assets related to its product and services business to Enghouse Systems Limited (“Enghouse”), a leading global telecommunication technology and solutions company that provides ne...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.